On August 19, Alnylam Pharmaceuticals rose 5.06% in regular trading, trading at $238.57/share, with Turnover of $35.19 million.
Within the Biotechnology sector where Alnylam Pharmaceuticals belongs, the overall sector showed broad strength. Among individual stocks, Moderna up 131.87%, BioNTech up 24.46%, Amgen up 3.24%, AbbVie up 2.27%, Forte BioSciences up 0.05%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)